Literature DB >> 1548925

Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations.

V Videm1, J L Svennevig, E Fosse, G Semb, A Osterud, T E Mollnes.   

Abstract

Complement activation after cardiopulmonary bypass is correlated with postoperative organ dysfunction. Heparin coating of the entire blood-contact surface of the cardiopulmonary bypass circuit has proved to reduce complement activation in vitro. A membrane oxygenator and tubing setup coated with functionally active heparin was compared with an uncoated, otherwise identical setup in 20 patients undergoing routine coronary bypass operations. The concentrations of C3 activation products and the terminal complement complex were measured in sensitive and specific enzyme immunoassays. Peak concentrations of C3 activation products were 90.1 (74.7 to 107.4) AU/ml (medians and 95% confidence intervals) and 52.4 (35.7 to 76.4) AU/ml with the uncoated and coated setups, respectively (p = 0.02). The corresponding concentrations of the terminal complement complex were 26.2 (20.1 to 37.5) AU/ml and 13.7 (11.1 to 25.1) AU/ml (p = 0.03). Blood loss from the mediastinal drains during the first 12 postoperative hours was 533 (416 to 975) ml in patients treated with the uncoated setup and 388 (313 to 579) ml in the coated treatment group (p = 0.06) and was significantly correlated with peak concentrations of the terminal complement complex (p = 0.01). There were no differences in neutrophil counts nor platelet numbers between the treatment groups. The approximate 45% reduction in complement activation with the heparin-coated cardiopulmonary bypass device indicates a substantial improvement of biocompatibility.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548925

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

2.  Disconnection of Cobe SMARxT tubing from the venous outlet of the Terumo Capiox SX25RX oxygenator during cardiopulmonary bypass.

Authors:  Jane Ottens; Robert A Baker; Andrew J Sanderson; Richard F Newland
Journal:  J Extra Corpor Technol       Date:  2010-06

3.  Poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit can reduce transfusion of platelet products compared to heparin-coated circuit during aortic arch surgery.

Authors:  Katsuhiro Hosoyama; Koki Ito; Shunsuke Kawamoto; Kiichiro Kumagai; Masatoshi Akiyama; Osamu Adachi; Satoshi Kawatsu; Konosuke Sasaki; Marina Suzuki; Yumi Sugawara; Yuya Shimizu; Yoshikatsu Saiki
Journal:  J Artif Organs       Date:  2016-02-24       Impact factor: 1.731

4.  Platelet activation and aggregation during normothermic cardiopulmonary bypass.

Authors:  Y Misawa; H Konishi; K Kawahito; K Fuse
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

5.  Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model.

Authors:  J Gong; R Larsson; K N Ekdahl; T E Mollnes; U Nilsson; B Nilsson
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

6.  Toward an artificial endothelium: Development of blood-compatible surfaces for extracorporeal life support.

Authors:  Teryn R Roberts; Mark R S Garren; Hitesh Handa; Andriy I Batchinsky
Journal:  J Trauma Acute Care Surg       Date:  2020-08       Impact factor: 3.697

Review 7.  Strategies to prevent intraoperative lung injury during cardiopulmonary bypass.

Authors:  Efstratios E Apostolakis; Efstratios N Koletsis; Nikolaos G Baikoussis; Stavros N Siminelakis; Georgios S Papadopoulos
Journal:  J Cardiothorac Surg       Date:  2010-01-11       Impact factor: 1.637

Review 8.  Role of the Complement System in the Response to Orthopedic Biomaterials.

Authors:  Yvonne Mödinger; Graciosa Q Teixeira; Cornelia Neidlinger-Wilke; Anita Ignatius
Journal:  Int J Mol Sci       Date:  2018-10-27       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.